Xiao Yang

Dr. Xiao Yang

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2023 in Hepatology International
Verified
Journal Article
Closed access
PDF file
MTMi Tang
Mi Tang
LXLiling Xiong
Liling Xiong
JCJianghui Cai
Jianghui Cai
JFJinzhu Fu
Jinzhu Fu
HLHong Liu
Hong Liu
XYXiao Yang
Xiao Yang

4 January 2023 in Nutrition & Metabolism
Verified
Journal Article
Open access
PDF file
LZLi Zhang
Li Zhang
LXLiling Xiong
Liling Xiong
LFLi Fan
Li Fan
HDHaoyang Diao
Haoyang Diao
MTMi Tang
Mi Tang
SXShaSha Xing
ShaSha Xing
Objective: Atherosclerosis (AS) is the major cause of cardiovascular disease, and dyslipidemia is a principal determinant of the initiation and progression of AS. Numerous works have analyzed the lipid signature of blood, but scarce information on the lipidome of vascular tissue is available. This study investigated the lipid profile in the aorta ofApoE−/−mice.Method: ApoE−/−mice were randomly divided into two groups: (1) the normal diet (ND) group and (2) the high-fat diet (HFD) group. After feeding for 8 weeks, the plasma low-density lipoprotein (LDL), total cholesterol (TC), and triglyceride (TGs) levels were measured. UHPLC-Q Exactive plus MS was used to assess the lipid profile using both positive and negative ionization modes.Results: LDL and TC levels were significantly increased in HFD mice, and lipid deposition, plaque area and collagen fiber levels were increased in HFD group. In addition, a total of 131 differential lipids were characterized, including 57 lipids with levels that were increased in the HFD group and 74 with levels that were decreased. Further analysis revealed that the levels of several differentially expressed phosphocholines (PCs) and lysophosphocholines (LPCs) were significantly increased. These PCs included PC (38:3), PC (36:4), PC (36:3), PC (36:2), PC (36:1), PC (34:1e), PC (34:1), PC (32:1), PC (18:0/18:1), and PC (38:5), and the LPCs included LPC (18:1), LPC (18:0) and LPC (16:0).Conclusion: Our findings indicate the presence of a comprehensive lipid profile in the vascular tissue of atherosclerotic mice, particularly involving PC and LPC, which exhibited significantly increased levels in AS.

24 January 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
XGXuejia Gong
Xuejia Gong
ELErdan Luo
Erdan Luo
LFLi Fan
Li Fan
WZWanggang Zhang
Wanggang Zhang
YYYan Yang
Yan Yang
SXShaSha Xing
ShaSha Xing
Respiratory syncytial virus (RSV) is a significant causative agent of bronchitis and pneumonia in infants and children. The identification and structural analysis of the surface fusion glycoprotein of RSV represents a pivotal advancement in the development of RSV prevention. This review provides a comprehensive summary of RSV monoclonal antibody (mAb) and vaccine clinical trials registered on ClinicalTrials.gov, emphasizing on the classification, name, target, phase, clinical outcomes, and safety data of RSV vaccination in newborns, infants and children. We also discuss the characteristics of the types of RSV vaccines for maternal immunity and summarize the current clinical research progress of RSV vaccination in pregnant women and their protective efficacy in infants. This review will provide new ideas for the development of RSV prevention for children in the future.

10 June 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
MTMi Tang
Mi Tang
JCJiang-Hui Cai
Jiang-Hui Cai
HDHao-Yang Diao
Hao-Yang Diao
WGWen-Mei Guo
Wen-Mei Guo
XYXiao Yang
Xiao Yang
SXShaSha Xing
ShaSha Xing
Peptide vaccine are a type of immunotherapy that are synthesized according to the amino acid sequence of known or predicted tumor antigen epitopes. They are safe and well tolerated and have shown exciting results in gynecologic oncology. However, no peptide vaccine has yet been licensed in this field. This review examines peptide vaccine clinical trials in gynecology registered on ClinicalTrials.gov through January 1, 2022, analyzes the global progress and current achievements of peptide vaccines in gynecology, and explores the efforts focused on devising new methods to boost immunotherapeutic outcomes, including the use of adjuvants, multi-epitope vaccines, combinations of helper T cell epitopes, personalized peptide vaccines, synthetic long peptides, new peptide delivery, and combination therapy.

1 March 2014 in Toxicology Letters
Verified
Journal Article
Closed access
JMJing Ma
Jing Ma
JYJiong Yu
Jiong Yu
XSXiaoru Su
Xiaoru Su
CZChengxing Zhu
Chengxing Zhu
XYXiao Yang
Xiao Yang
JLJianxin Lyu
Jianxin Lyu

25 June 2023 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
RZRui Zhang
Rui Zhang
SSShuping Shuai
Shuping Shuai
HZHongxi Zhang
Hongxi Zhang
JCJianghui Cai
Jianghui Cai
NCNa Cui
Na Cui
XYXiao Yang
Xiao Yang
Background: Intravenous immunoglobulin (IVIG) has been the mainstay of treatment for Kawasaki disease (KD) over the past decades. However, 10–20% of KD patients are resistant to IVIG treatment which puts those patients at high risk of coronary artery lesions (CALs). Therefore, it is important to predict whether patients will be resistant to IVIG before the treatment. This study aimed to investigate the risk factors for IVIG non-responsive patients with KD. Methods: This study enrolled patients diagnosed with KD and divided them into two groups, IVIG responders and IVIG non-responders. We compared the differences in demographics and clinical data between the two groups. Differences among the groups were analyzed by ANOVA and Chi-square analysis. Predictors of IVIG resistance were determined by multiple logistic regression analysis and receiver operating characteristic (ROC) curve analysis. Results: In total, 907 KD patients were reviewed, with 841 IVIG responders and 66 IVIG non-responders. Patients in IVIG responders were younger than IVIG non-responders. The length of hospitalization of the IVIG non-responders was significantly longer than IVIG responders. The neutrophils%, C-reaction protein (CRP), and CRP/albumin ratio in IVIG responders were significantly lower than in IVIG non-responders (P < 0.05). The lymphocyte% and Albumin in IVIG responders were significantly higher than in IVIG non-responders. Multivariable logistic regression analysis demonstrated that albumin (OR = 0.881, 95% CI, 0.781 to 0.994, p-value = 0.039) was an independent risk factor for predicting IVIG resistance. The area under the ROC curve was 0.644, with a cut-off of ≤ 33.4 g/L determined by Youden’s index. The sensitivity and specificity in predicting IVIG resistance were 40.91% and 83.47%, respectively. Conclusion: Albumin can serve as a potential predicting marker for IVIG resistance in KD. A lower albumin level may be useful for identifying KD patients with a high risk of IVIG resistance to guide further therapy strategies.